The antipsoriatic drug, anthralin, inhibits protein kinase C — implications for its mechanism of action-Reference-Cited by-同舟云学术

The antipsoriatic drug, anthralin, inhibits protein kinase C — implications for its mechanism of action

Published:1992-06 Issue:3 Volume:284 Page:179-183
ISSN:0340-3696
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Hegemann L.,Fruchtmann R.,van Rooijen L. A. A.,Müller-Peddinghaus R.,Mahrle G.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF00372713.pdf

Reference32 articles.

1. Bisschop A, Uijtewaal B, Vankan PMJ, Rooijen LAA van (1984) Anthralin and 12-O-tetradecanoylphorbol-13-acetate differentially affect rat hepatic ornithine decarboxylase activity. 25th Meeting of the Dutch Federation of Medical Scientific Societies, Rotterdam, The Netherlands, 13?15 April

2. Blumberg PM (1988) Protein kinase C as the receptor for the phorbol ester tumor promotors: Sixth Rhoads Memorial Award Lecture. Cancer Res 48: 1?8

3. Bock BG, Burns R (1963) Tumor promoting properties of anthralin (1.8.9 anthracenetriol). J Natl Cancer Inst 30: 393?397

4. Bonnekoh B, Farkas B, Geisel J, Mahrle G (1990) Lactate dehydrogenase release as an indicator of dithranol-induced membrane injury in cultured human keratinocytes. Arch Dermatol Res 282: 325?329

5. Cerutti PA (1985) Prooxidant states and tumor promotion. Science 227: 375?381

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical treatments for scalp psoriasis;Cochrane Database of Systematic Reviews;2016-02-26

2. Psoriasis;Pathology Case Reviews;2011-01

3. TREATMENT OF PATIENTS HOSPITALIZED FOR PSORIASIS;Dermatologic Clinics;2000-07

4. Psoriasis Upregulated Phorbolin-1 Shares Structural but not Functional Similarity to the mRNA-Editing Protein Apobec-1;Journal of Investigative Dermatology;1999-08

5. Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis;Expert Opinion on Investigational Drugs;1997-10